Search results for " Behcet"

showing 10 items of 10 documents

PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease

2010

OBJECTIVES: To investigate potential associations between the PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA (GpIIIa) gene and venous thrombosis and other clinical manifestations in Italian patients with Behçet's disease (BD). METHODS: Two hundred consecutive Italian patients satisfying the International Study Group criteria for BD who were followed up for seven years and 241 healthy Italian age- and gender-matched blood donors were molecularly genotyped for the PlA1/A2 polymorphism of the platelet GpIIIa gene; 118 and 117 of the 200 BD patients were also respectively genotyped for factor V Leiden and prothrombin gene G20210A polymorphisms. A standard microlymphocytotoxicit…

AdultBlood PlateletsMaleVenous ThrombosisPolymorphism GeneticAdolescentGenotypeBehcet SyndromeIntegrin beta3Factor VPLA1/2 polymorphism Behcet's diseaseYoung AdultHuman PlateletGene FrequencyGeneticHumansAntigens Human PlateletFemaleProthrombinAdolescent; Adult; Antigens Human Platelet; Blood Platelets; Factor V; Female; Gene Frequency; Genotype; Humans; Integrin beta3; Male; Polymorphism Genetic; Prothrombin; Young Adult; Behcet Syndrome; Venous ThrombosisAntigensPolymorphism
researchProduct

Clinical manifestations of Behçet's disease in 137 Italian patients: Results of a multicenter study

2005

Objective. To determine the type and frequency of clinical features of Behcets disease in a population of Italian patients. Methods. We retrospectively v studied 137 Italian patients (76 males and 61 females, age at onset 29.6 +/- 12.2 [mean +/-SD] Years) seen consecutively in nine different referral centers. The duration of follow-up (it study entry was 10.9 +/- 8.2 years. Virtually all patients fulfilled the classification criteria developed by the International Study Group for Behcets disease. The clinical manifestations of the patients were recorded by the attending physicians using specifically designed forms. \ Results. The most frequent manifestations at disease onset were oral (78.3…

AdultMaleUveitisStomatitisItalyBehcet Syndromesigns and symptomHumansStomatitis AphthousFemaleAphthousAdult; Behcet Syndrome; Female; Humans; Italy; Male; Retrospective Studies; Stomatitis Aphthous; UveitisRetrospective Studies
researchProduct

Vascular endothelial growth factor gene polymorphisms in Behçet's disease

2004

Objective. To evaluate potential associations of vascular endothelial growth factor (VEGF) gene polymorphisms with Behçet's disease (BD) and disease expression. Methods. Case patients were 122 consecutive Italian patients with BD followed at the Rheumatology, Ophthalmology, and Neurology Units in Bologna, Ferrara, Milano, Palermo, Potenza, Prato, Reggio Emilia, and Trento over a 3-year period (1997-99) and who satisfied the International Study Group criteria for BD. Also selected as a control group were 200 healthy age and sex matched blood donors. All patients with BD and controls were genotyped by polymerase chain reaction and allele-specific oligonucleotide techniques for +936 C/T (rs302…

AdultMaleVascular Endothelial Growth Factor Aclinical manifestationsPolymorphism GeneticAdolescentGenotypeBehcet SyndromeVEGF productionBehcet's diseaseVEGF polymorphismGene FrequencyLeukocytes MononuclearHumansAdolescent; Adult; Behcet Syndrome; Cells Cultured; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leukocytes Mononuclear; Male; Vascular Endothelial Growth Factor A; Polymorphism GeneticFemaleGenetic Predisposition to DiseaseCells Cultured
researchProduct

Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis

2004

OBJECTIVE: To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behçet's disease (BD). METHODS: Included were 118 consecutive Italian BD patients followed over a 3-year period (1997-1999) who satisfied the International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for factor V Leiden and prothrombin gene G20210A polymorphisms. RESULTS: Vascular lesions were observed in …

AdultMaleVenous ThrombosisFactor V Leiden mutation Prothrombin G20210A mutationAdolescentGenotypeBehcet SyndromeFactor VMiddle AgedBehc ̧et’s disease; Deep vein thrombosis; Factor V Leiden mutation Prothrombin G20210A mutationAdolescent; Adult; Behcet Syndrome; Factor V; Female; Gene Frequency; Genotype; Humans; Italy; Male; Middle Aged; Prothrombin; Risk Factors; Venous Thrombosis; Point MutationGene FrequencyItalyDeep vein thrombosiRisk FactorsFactor V Leiden mutationHumansPoint MutationFemaleProthrombinProthrombin G20210A mutationBehcet’s disease
researchProduct

CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease

2012

OBJECTIVE: To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behcet's disease (BD) in a cohort of Italian patients. METHODS: One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations. RESULTS: The distribution of the CCR5Δ32 genotype differed between BD patients and controls…

AdultMalemedicine.medical_specialtyHeterozygoteReceptors CCR5Behcet's disease CCR5 polymorphismBehcet's diseaseGastroenterologyRheumatologyGeneticGene FrequencyInternal medicineGenotypeReceptorsMedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismAllele frequencyPolymorphism Geneticbusiness.industryBehcet SyndromeHomozygoteCase-control studyOdds ratiomedicine.diseaseBeḩet's disease; CC chemokine receptor 5 Δ32 olymorphism; Chemokines; Disease manifestations; Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5; Rheumatology; Pharmacology (medical)Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5ItalyHLA-B AntigensCase-Control StudiesImmunologyCohortFemalebusinessCC chemokine receptorsCCR5
researchProduct

Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients.

2007

Objective. To investigate potential associations between the � 463G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical expression of, Behcet's disease (BD). Methods. One hundred and seventy-five Italian patients who satisfied the International Study Group criteria for BD and 235 healthy age- and sex-matched blood donors were genotyped for the �463G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of clinical manifestations. Results. The distribution of allele and genotype frequencies of the MPO �463A/G polymorphism did not differ significantly between the BD patients and the healthy…

AdultMalemedicine.medical_specialtySystemic diseaseAdult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism GeneticHeterozygoteGenotypeBehcet's diseaseBehçet's disease; Disease manifestation; Myeloperoxidase; Myeloperoxidase gene polymorphism; Adult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism Genetic; Rheumatology; Pharmacology (medical)Promoter RegionsRheumatologyGeneticGene FrequencyInternal medicineGenotypemedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismPromoter Regions GeneticPeroxidasePolymorphism Geneticbiologybusiness.industryBehcet SyndromeHistocompatibility TestingOdds ratiomedicine.diseaseRheumatologyGenotype frequencyMyeloperoxidaseImmunologybiology.proteinFemalebusinessRheumatology (Oxford, England)
researchProduct

Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansio…

2010

INTRODUCTION: Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-alpha) that has been introduced recently for Behçet's disease (BD) patients who were resistant to standard treatment. The aim of this study was to analyse the functional changes of Vgamma9/Vdelta2 T lymphocytes in both active and inactive disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. METHODS: We investigated 1) cell expansion, 2) expression of TNFRII receptor, 3) perforin and gamma interferon (IFN) content, 4) release of granzyme A (GrA) and 5) phenotype changes, in vitro and in vivo, in Vgamma9/Vdelta2 T lymphocytes by means of fluores…

Behcetgamma delta T lymphocytes Behcetgamma delta T lymphocyte
researchProduct

La malattia di Behcet: note per la diagnosi, case report e raccomandazioni per la pratica clinica.

2007

Malattia di BehcetSettore MED/35 - Malattie Cutanee E VenereeSettore MED/40 - Ginecologia E Ostetricia
researchProduct

A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry

2017

Abstract Background Behçet’s disease is a rare multi-systemic inflammatory disease with unknown etiology which involves principally oral and genital mucosa, skin and eyes. Average age at onset of the disease is about 25-30 years, but it may be diagnosed before the age of 16. It is not very rare in Italy, even though there are limited data concerning epidemiology. Aim of this study is to describe the baseline data of an Italian cohort of patients with as having BD or probable BD. Methods We described the baseline data of the first national epidemiological study on children coming from 16 Italian Pediatric Rheumatologic Centers diagnosed by the treating physicians as having Behçet’s Disease. …

Malelcsh:Diseases of the musculoskeletal systemDiagnostic criteriaCross-sectional studyConstitutional symptomsBehcet's diseasePediatricsCohort StudiesBehçet’s diseaseBiological Factors0302 clinical medicineEpidemiologyImmunology and AllergyLongitudinal StudiesRegistries030212 general & internal medicineBehçet’s disease Children Clinical features Diagnostic criteria Treatment Pediatrics Perinatology and Child Health Rheumatology Immunology and AllergyChildChildrenBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Adolescent; Behcet Syndrome; Biological Factors; Child; Cohort Studies; Cross-Sectional Studies; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Italy; Longitudinal Studies; Male; Registries; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergyeducation.field_of_studyBehçet's diseaseBehcet Syndromelcsh:RJ1-570Perinatology and Child HealthItalySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACohortFemaleImmunosuppressive AgentsResearch ArticleCohort studyBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergymedicine.medical_specialtyAdolescentPopulationBehçet's disease03 medical and health sciencesRheumatologyInternal medicinemedicineHumansBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyeducationGlucocorticoids030203 arthritis & rheumatologybusiness.industrylcsh:PediatricsClinical featuresmedicine.diseaseTreatmentCross-Sectional StudiesClinical featurePediatrics Perinatology and Child HealthEtiologylcsh:RC925-935business
researchProduct

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct